Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.85 USD
Change Today -0.08 / -1.62%
Volume 564.1K
CERS On Other Exchanges
Symbol
Exchange
CERS is not on other exchanges.
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

cerus corp (CERS) Snapshot

Open
$4.92
Previous Close
$4.93
Day High
$4.97
Day Low
$4.81
52 Week High
01/5/15 - $7.03
52 Week Low
10/13/14 - $3.60
Market Cap
469.4M
Average Volume 10 Days
833.9K
EPS TTM
$-0.75
Shares Outstanding
96.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CERUS CORP (CERS)

cerus corp (CERS) Related Bloomberg News

View More Bloomberg News

cerus corp (CERS) Related Businessweek News

No Related Businessweek News Found

cerus corp (CERS) Details

Cerus Corporation operates as a biomedical products company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, including viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company’s INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion; and INTERCEPT Blood System for red blood cells is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. Cerus Corporation markets its platelet and plasma systems through its direct sales force and distributors. The company has collaboration with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

144 Employees
Last Reported Date: 03/16/15
Founded in 1991

cerus corp (CERS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $520.8K
Co-Founder, Chief Scientific Officer and Corp...
Total Annual Compensation: $426.5K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $308.4K
President of Cerus Europe and EEMEA
Total Annual Compensation: $281.6K
Senior Vice President of Regulatory Affairs, ...
Total Annual Compensation: $375.6K
Compensation as of Fiscal Year 2014.

cerus corp (CERS) Key Developments

Cerus Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Revenue Guidance for the Full Year of 2015

Cerus Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $8,830,000 compared to $8,601,000 a year ago. This reflects a 32% year over year increase in INTERCEPT disposable kit demand, offset in part by a declining Euro exchange rate, resulting in a 3% year over year increase in reported second quarter revenue. Loss from operations was $15,525,000 compared to $11,004,000 a year ago. Net loss before income taxes was $18,007,000 compared to $7,545,000 a year ago. Net loss was $15,972,000 or $0.17 per basic and diluted share compared to $7,589,000 or $0.16 per diluted share a year ago. Net losses for the second quarter of 2015 were impacted by the above discussed operating losses and mark-to-market adjustments of the company's outstanding warrants to fair value, which resulted in non-cash charges of $2.7 million during the second quarter of 2015 compared to $3.5 million in non-cash gains during the comparable period in 2014. For the six months period, the company reported revenue of $16,522,000 compared to $16,467,000 a year ago. Loss from operations was $29,896,000 compared to $20,223,000 a year ago. Net loss before income taxes was $27,448,000 compared to $7,732,000 a year ago. Net loss was $25,432,000 or $0.30 per diluted share compared to $7,814,000 or $0.28 per diluted share a year ago. The company provided revenue guidance for the full year of 2015. The company continues to expect full-year revenues of $36 million to $38 million.

Cerus Corporation and Unyts Enter into Agreement for Use of Intercept Platelets and Plasma

Cerus Corporation announced that Unyts has signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. Unyts provides blood components to eight counties in Western New York, supplying approximately 5,000 platelet and 11,000 plasma units per year.

Cerus Corporation Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 02:30 PM

Cerus Corporation Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 02:30 PM. Venue: Le Parker Meridian, 119 West 56th Street, New York, NY 10019, United States. Speakers: William M. Greenman, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CERS:US $4.85 USD -0.08

CERS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €36.89 EUR +0.085
View Industry Companies
 

Industry Analysis

CERS

Industry Average

Valuation CERS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.7x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CERUS CORP, please visit www.cerus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.